You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Electrical System for Rapid Bacterial Cultures

    SBC: TECHSHOT, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad, long-term objective of the proposed project Electrical System for Rapid Bacterial Cultures is to develop an automated electrical impedance analyzer for measuring bacterial growth in contaminated blood. Thepurpose of the System is to hasten the time to diagnose sepsis from 1-2 days down to a few hours. The specific aims of the project are to (1) bui ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic Antibodies for Rabies

    SBC: Trellis Bioscience, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody to Respiratory Syncytial Virus (RSV) that is now bein ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutic Antibodies for Bacteria

    SBC: Trellis Bioscience, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody to Respiratory Syncytial Virus (RSV) that is now bein ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid Response Vaccines for Botulinum Neurotoxins

    SBC: Iterative Therapeutics Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currentlyavailable pentavalent toxoid vaccine requires multiple boosters before being effective, and protects unequally against the different BoNT serotyp ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Identification of novel influenza antivirals

    SBC: Arisan Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): The influenza A virus represents one of the greatest global human health risks. Although vaccines provide significant protection from seasonal flu infections they still account for an estimated 36,000 deaths and 200,000hospitalizations per year in the US alone. Furthermore, the inherent time involved in development, production and distribution of vaccines limit ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. A Combination Therapy Approach to Treating Drug Resistant Fungal Infections

    SBC: Amplyx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is an urgent need to discover more effective therapeutic regimens for fungal infections. Nosocomial infections caused by Candida albicans have a 50% mortality rate. Aspergillosis is a leading cause of death in organ transplant recipients, as well as patients suffering from cancer and auto-immune disorders. The annual cost of treating fungal infections is ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Origami MALE CONDOM-3: Feasibility and Acceptability Study, Phase 1 Clinical Resear

    SBC: Strata Various Product Design            Topic: NIAID

    DESCRIPTION (provided by applicant): The primary objective of this project is to build on prior Phase 1 research to improve product sensitivity properties, to refine and test modifications of the Origami Male Condom 1 (OMC 1), and develop a more consumer-acceptable device exclusively for vaginal-penile intercourse, the Origami Male Condom 3 (OMC 3). Made of custom formulated biocompatible, viral-i ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. SAMBA HIV-1 Semi-quantitative Test for resource limited settings

    SBC: DIAGNOSTICS FOR THE REAL WORLD LIMITED            Topic: NIAID

    DESCRIPTION (provided by applicant): The ultimate aim of this project is to develop a CE-marked and/or FDA-approved diagnostic platform for viral load monitoring of HIV-1 infected patients in point-of-care (POC) and resource- limited settings. Currently available viral load tests are not suitable for such settings due to their inherent high cost, complexity and size, thus patients, especially in t ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. An intramedullary device for less invasive surgical fixation of wrist fractures

    SBC: ENDOORTHOPAEDICS, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): The distal radius is one of the most common sites of bone fracture and is the most common fracture site in the upper extremity, accounting for approximately 10% of all fractures in adults. Approximately 25% of patients(~80,000/year) require surgery to correctly repair this bone, and current practice requires the surgeon to disrupt the soft tissues surrounding t ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Phage Display Peptide Probes for Imaging Early Response to Cancer Therapy

    SBC: ACADUCEUS PHARMACEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this SBIR proposal is to develop novel molecular imaging markers for monitoring tumor early response and efficacy to anti-angiogenic treatment regimens. Anti-angiogenic therapy represents an exciting advance in the management of cancer. Targeting of the vasculature has been shown to benefit patients with several types of malignancies. Hundr ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government